On Aug. 26, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency in the United Kingdom had granted expanded conditional marketing authorization for Nuvaxovid (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents aged 12 through 17.